North America Antimicrobial Resistance Diagnostics Market Size, Share & Industry Trends Analysis Report By Technology, By End User (Hospitals, Diagnostic Laboratories and Pharmaceutical, Biotechnology Companies), By Pathogen, By Country and Growth Forecas

North America Antimicrobial Resistance Diagnostics Market Size, Share & Industry Trends Analysis Report By Technology, By End User (Hospitals, Diagnostic Laboratories and Pharmaceutical, Biotechnology Companies), By Pathogen, By Country and Growth Forecast, 2022 - 2028

The North America Antimicrobial Resistance Diagnostics Market would witness market growth of 4.9% CAGR during the forecast period (2022-2028).

Antimicrobial resistance (AMR) in organisms can develop through a number of routes. The drug may deteriorate or undergo chemical modification (by phosphorylation, nucleotidylation, acetylation, ADP-ribosylation, glycosylation, mono-oxygenation). Either the medication intake can be stopped or the efflux can be increased. Some resistance defenses work by reprogramming the production of cell walls.

The antimicrobial may become ineffective if the target molecule undergoes even minor alterations, such as a point alteration in the ribosomal protein. AMR is complicated by the enormous variety of antimicrobial drugs and resistance mechanisms. Genotypic (nucleic acid-based) approaches to find the resistances that are specifically sought, while phenotypic testing, a test that determines whether the bacterium grows in the environment of the antibiotic, is necessary for accurate antibiotic resistance diagnoses.

These techniques function regardless of the mechanism of resistance and provide answers to the relevant concerns of which antibiotic is effective and what dosage should be used during treatment. A bacterial isolate is continuously exposed to a variety of antimicrobials using traditional diagnostic techniques such as broth microdilution, gradient tests, disk diffusion, agar dilution, and breakpoint tests before growth is visually detected. The performance and sensitivity of optical systems can be further improved by the use of sophisticated fiber optics, optoelectronic systems, microfluidics, and indicator dyes responsive to redox state or pH.

Two of the most common illnesses reported in the US are MRSA and c. diff. The 2019 Antibiotic Resistance (AR) Threats Report from the CDC estimates that more than 35,000 people pass away as a result of antimicrobial resistance. Therefore, the CDC started collaborating with partners mostly through Antibiotic Resistance (AR) Solutions Initiative to promote aggressive action and equip the country to provide a complete response. The AR Solutions Initiative makes investments in the country's infrastructure to identify, address, contain, and mitigate resistant illnesses in the food, community, and healthcare sectors. Therefore, the region presents lucrative growth opportunities for the antimicrobial resistance diagnostics market as a result of a growing number of government initiatives to combat the rising AMR levels.

The US market dominated the North America Antimicrobial Resistance Diagnostics Market by Country in 2021; thereby, achieving a market value of $1,530.9 million by 2028. The Canada market is experiencing a CAGR of 7.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 6.4% during (2022 - 2028).

Based on Technology, the market is segmented into PCR, Immunoassay, NGS, Microbiology Culture, Mass Spectrometry, Rapid & Point of Care and Others. Based on End User, the market is segmented into Hospitals, Diagnostic Laboratories and Pharmaceutical, Biotechnology Companies & Others. Based on Pathogen, the market is segmented into Methicillin Resistant Staphylococcus Aureus (MRSA), Clostridium Difficile (CD), Drug Resistant Campylobacter (DRC), Drug Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS) and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Danaher Corporation, Accelerate Diagnostics, Inc., Hologic, Inc., Visby Medical, Inc., Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd) and Molsid S.A.S.

Scope of the Study

Market Segments covered in the Report:

By Technology

• PCR
• Immunoassay
• NGS
• Microbiology Culture
• Mass Spectrometry
• Rapid & Point of Care
• Others

• Hospitals
• Diagnostic Laboratories
• Pharmaceutical, Biotechnology Companies & Others

• Methicillin Resistant Staphylococcus Aureus (MRSA)
• Clostridium Difficile (CD)
• Drug Resistant Campylobacter (DRC)
• Drug Resistant Streptococcus Pneumoniae (DRSP)
• Drug Resistant Neisseria Gonorrhoeae (DRNG)
• Drug Resistant Salmonella (DRNTS)
• Others

• US
• Canada
• Mexico
• Rest of North America

• Abbott Laboratories
• BioMérieux S.A.
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
• Danaher Corporation
• Accelerate Diagnostics, Inc.
• Hologic, Inc.
• Visby Medical, Inc.
• Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd)
• Molsid S.A.S.

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free